PMID- 27884660
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20220316
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Print)
IS  - 1056-8727 (Linking)
VI  - 31
IP  - 2
DP  - 2017 Feb
TI  - Exenatide improves diastolic function and attenuates arterial stiffness but does 
      not alter exercise capacity in individuals with type 2 diabetes.
PG  - 449-455
LID - S1056-8727(16)30397-X [pii]
LID - 10.1016/j.jdiacomp.2016.10.003 [doi]
AB  - BACKGROUND: Exercise is recommended as a cornerstone of treatment for type 2 
      diabetes mellitus (T2DM), however, it is often poorly adopted by patients. Even 
      in the absence of apparent cardiovascular disease, persons with T2DM have an 
      impaired ability to carry out maximal and submaximal exercise and these 
      impairments are correlated with cardiac and endothelial dysfunction. 
      Glucagon-like pepetide-1 (GLP-1) augments endothelial and cardiac function in 
      T2DM. We hypothesized that administration of a GLP-1 agonist (exenatide) would 
      improve exercise capacity in T2DM. METHODS AND RESULTS: Twenty-three participants 
      (64+/-4years; mean+/-SE) with uncomplicated T2DM were randomized in a double-blinded 
      manner to receive either 10mug BID of exenatide or matching placebo after baseline 
      measurements. Treatment with exenatide did not improve VO(2peak) (P=0.1464) or 
      VO(2) kinetics (P=0.2775). Diastolic function, assessed via resting lateral E:E', 
      was improved with administration of exenatide compared with placebo (Placebo Pre: 
      7.6+/-1.0 vs. Post: 8.4+/-1.2 vs. Exenatide Pre: 8.1+/-0.7 vs. Post: 6.7+/-0.6; 
      P=0.0127). Additionally, arterial stiffness measured by pulse wave velocity, was 
      reduced with exenatide treatment compared with placebo (Placebo Pre: 10.5+/-0.8 vs. 
      Post: 11.5+/-1.1s vs. Exenatide Pre: 11.4+/-1.8 vs. Post: 10.2+/-1.4s; P=0.0373). 
      Exenatide treatment did not improve endothelial function (P=0.1793). CONCLUSIONS: 
      Administration of exenatide improved cardiac function and reduced arterial 
      stiffness, however, these changes were not accompanied by improved functional 
      exercise capacity. In order to realize the benefits of this drug on exercise 
      capacity, combining exenatide with aerobic exercise training in participants with 
      T2DM may be warranted.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Scalzo, Rebecca L
AU  - Scalzo RL
AD  - Division of Endocrinology, Department of Medicine, University of Colorado School 
      of Medicine (UCSOM), Denver, Colorado 80215.
FAU - Moreau, Kerrie L
AU  - Moreau KL
AD  - Division of Geriatrics, Department of Medicine, University of Colorado School of 
      Medicine (UCSOM), Denver, Colorado 80215; Center for Women's Health Research, 
      Department of Medicine, University of Colorado School of Medicine (UCSOM), 
      Denver, Colorado 80215; VAMC-Geriatric Research Education and Clinical Center 
      (GRECC), Denver, Colorado 80215.
FAU - Ozemek, Cemal
AU  - Ozemek C
AD  - Division of Geriatrics, Department of Medicine, University of Colorado School of 
      Medicine (UCSOM), Denver, Colorado 80215.
FAU - Herlache, Leah
AU  - Herlache L
AD  - Division of General Internal Medicine, Department of Medicine, University of 
      Colorado School of Medicine (UCSOM), Denver, Colorado 80215.
FAU - McMillin, Shawna
AU  - McMillin S
AD  - Division of General Internal Medicine, Department of Medicine, University of 
      Colorado School of Medicine (UCSOM), Denver, Colorado 80215.
FAU - Gilligan, Sarah
AU  - Gilligan S
AD  - Division of General Internal Medicine, Department of Medicine, University of 
      Colorado School of Medicine (UCSOM), Denver, Colorado 80215.
FAU - Huebschmann, Amy G
AU  - Huebschmann AG
AD  - Center for Women's Health Research, Department of Medicine, University of 
      Colorado School of Medicine (UCSOM), Denver, Colorado 80215; Division of General 
      Internal Medicine, Department of Medicine, University of Colorado School of 
      Medicine (UCSOM), Denver, Colorado 80215.
FAU - Bauer, Tim A
AU  - Bauer TA
AD  - Division of General Internal Medicine, Department of Medicine, University of 
      Colorado School of Medicine (UCSOM), Denver, Colorado 80215.
FAU - Dorosz, Jennifer
AU  - Dorosz J
AD  - Division of Cardiology, Department of Medicine, University of Colorado School of 
      Medicine (UCSOM), Denver, Colorado 80215.
FAU - Reusch, Jane E B
AU  - Reusch JE
AD  - Division of Endocrinology, Department of Medicine, University of Colorado School 
      of Medicine (UCSOM), Denver, Colorado 80215; Center for Women's Health Research, 
      Department of Medicine, University of Colorado School of Medicine (UCSOM), 
      Denver, Colorado 80215; Veterans Administration Medical Center (VAMC), Denver, 
      Colorado 80215.
FAU - Regensteiner, Judith G
AU  - Regensteiner JG
AD  - Center for Women's Health Research, Department of Medicine, University of 
      Colorado School of Medicine (UCSOM), Denver, Colorado 80215; Division of General 
      Internal Medicine, Department of Medicine, University of Colorado School of 
      Medicine (UCSOM), Denver, Colorado 80215. Electronic address: 
      judy.regensteiner@ucdenver.edu.
LA  - eng
GR  - K23 HL118133/HL/NHLBI NIH HHS/United States
GR  - T32 HL007171/HL/NHLBI NIH HHS/United States
GR  - UL1 RR025780/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20161007
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Peptides)
RN  - 0 (Venoms)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Aged
MH  - Arteries/drug effects/physiopathology
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism/physiopathology
MH  - Diabetic Angiopathies/*prevention & control
MH  - Diabetic Cardiomyopathies/*prevention & control
MH  - Double-Blind Method
MH  - Endothelium, Vascular/drug effects/physiopathology
MH  - Exenatide
MH  - Exercise Tolerance/drug effects
MH  - Female
MH  - Follow-Up Studies
MH  - Glucagon-Like Peptide 1/agonists/metabolism
MH  - Heart Ventricles/drug effects/physiopathology
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/drug effects
MH  - Peptides/adverse effects/*therapeutic use
MH  - Pulse Wave Analysis
MH  - Sedentary Behavior
MH  - Vascular Stiffness/*drug effects
MH  - Venoms/adverse effects/*therapeutic use
MH  - Ventricular Dysfunction, Left/complications/*prevention & control
PMC - PMC5787373
MID - NIHMS935725
OTO - NOTNLM
OT  - Cardiovascular diseases
OT  - Diabetes mellitus
OT  - Exercise
OT  - GLP-1
OT  - VO(2)peak
EDAT- 2016/11/26 06:00
MHDA- 2018/02/27 06:00
PMCR- 2018/01/28
CRDT- 2016/11/26 06:00
PHST- 2016/08/12 00:00 [received]
PHST- 2016/09/19 00:00 [revised]
PHST- 2016/10/03 00:00 [accepted]
PHST- 2016/11/26 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
PHST- 2016/11/26 06:00 [entrez]
PHST- 2018/01/28 00:00 [pmc-release]
AID - S1056-8727(16)30397-X [pii]
AID - 10.1016/j.jdiacomp.2016.10.003 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2017 Feb;31(2):449-455. doi: 
      10.1016/j.jdiacomp.2016.10.003. Epub 2016 Oct 7.